Lifevantage Corp director Dayton Judd reported open-market purchases of the company’s common stock. He bought 10,500 shares on March 2, 2026 at $4.53, 18,097 shares on February 27, 2026 at $4.63, and 4,600 shares on February 26, 2026 at $4.58, totaling 33,197 shares.
After these transactions, Judd directly owns 80,359 shares. The filing also shows 749,325 shares held indirectly through Sudbury Capital Fund, LP, an investment entity with which he is associated.
LifeVantage director Darwin Lewis bought 3,955 shares of company common stock in an open‑market transaction at a weighted average price of $5.2216 per share. After this purchase on February 9, 2026, he directly owns 135,508 LifeVantage shares.
LifeVantage Corporation filed a current report describing two key updates. The company issued a press release announcing financial results for the three and six months ended December 31, 2025, which is furnished as Exhibit 99.1. The report also discloses that President and Chief Executive Officer Steven R. Fife has decided to retire and will resign as CEO and from the board, with his resignation expected to be effective in April 2026. The company states that Mr. Fife’s decision to retire is not due to any disagreement regarding operations, financial policies, or practices, and additional details are provided in a second press release furnished as Exhibit 99.2.
LifeVantage Corporation reported weaker results for the quarter ended December 31, 2025 as revenue fell to $48.9 million from $67.8 million a year earlier, mainly from lower sales of its MindBody GLP-1 System™. Net income declined to $0.3 million from $2.6 million, with gross margin pressured by about $2.4 million of inventory obsolescence tied to this product line.
For the first six months, revenue was $96.5 million versus $115.0 million, and net income was $2.4 million versus $4.4 million. Active accounts fell 21.2% year over year to 115,000, reflecting fewer independent consultants and customers. The company completed a $4.2 million acquisition of LoveBiome assets, adding a new gut-health product line, and ended the period with $10.2 million in cash and no borrowings on its $5.0 million credit facility.
Lifevantage Corp director Michael Beindorff reported gifting company stock to a family trust. On 11/25/2025, he transferred 7,819 shares of Lifevantage common stock in a transaction coded "G," which indicates a gift with a reported price of $0 per share.
After this transaction, he directly owned 27,570 shares and indirectly held 51,625 shares through the Michael A. Beindorff Trust, where he and his spouse are trustees. Additional indirect holdings include 126 shares held by his spouse as custodian for minor children and 5,500 shares held by his spouse.
LifeVantage Corporation disclosed that two senior executives plan to leave the company in December 2025. On December 3, 2025, Chief Marketing Officer Julie Boyster notified the company of her intention to resign from that role effective December 12, 2025 to pursue other business opportunities.
On the same date, Chief Information and Innovation Officer Todd Thompson informed LifeVantage that he intends to resign from his role effective December 24, 2025, also to pursue other business opportunities. These changes affect the leaders overseeing the company’s marketing and information/innovation functions.
LifeVantage Corp (LFVN) director Michael A. Beindorff reported a sale of company stock in a Form 4 filing. On 11/19/2025, a trust for which he and his spouse serve as trustees sold 12,607 shares of LifeVantage common stock at a weighted average price of $6.4198 per share, with individual trades executed between $6.39 and $6.48. After this transaction, he reported beneficial ownership of 43,806 shares held by the trust, 35,389 shares held directly, 126 shares held by his spouse as custodian for minor children, and 5,500 shares held by his spouse.
LifeVantage Corporation filed a Form S-8 to register securities for issuance under the LifeVantage Corporation 2017 Long‑Term Incentive Plan. The registration becomes effective upon filing in accordance with Rule 462(a).
The filing incorporates by reference the company’s most recent Form 10‑K, Form 10‑Q, and certain Form 8‑K reports. Exhibits include a legal opinion on the validity of the securities, auditor and counsel consents, and the plan document. The company states standard Delaware-law indemnification provisions for directors and officers and notes the SEC’s position that indemnification for Securities Act liabilities is unenforceable.
LifeVantage identifies itself as an accelerated filer and a smaller reporting company.
LifeVantage Corporation reported final results from its fiscal 2026 annual meeting held on November 6, 2025. Quorum was achieved with 9,571,454 shares (75.41%) represented out of 12,691,009 outstanding as of the record date.
All seven director nominees were elected. Stockholders approved, on an advisory basis, executive compensation with 7,420,820 votes for. They ratified Deloitte & Touche LLP as independent auditor with 9,539,267 votes for. An amendment to the 2017 Long‑Term Incentive Plan was approved with 5,382,441 votes for.
LifeVantage (LFVN) reported an insider equity grant. A director acquired 13,531 shares of common stock on 11/06/2025, reflected at $7.76 per share, which the filing notes equals the weighted average closing price over the ten trading days ending the day before the grant.
The grant will vest in a single installment on November 6, 2026, subject to the director’s continuous service. Following this grant, the director beneficially owns 23,999 shares, held directly.